FIVE PRIME THERAPEUTICS INC Form 8-K January 19, 2016

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 18, 2016

Five Prime Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction 001-36070 (Commission 26-0038620 (I.R.S. Employer

of incorporation)

File Number)

Identification No.)

Two Corporate Drive

94080

Edgar Filing: FIVE PRIME THERAPEUTICS INC - Form 8-K

South San Francisco, California (Address of principal executive offices) (Zip Code) Registrant s telephone number, including area code: (415) 365-5600

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 18, 2016, Julie Hambleton notified Five Prime Therapeutics, Inc. (the Company) that she will resign as Executive Vice President and Chief Medical Officer and an employee of the Company, effective as of February 15, 2016, in order to pursue other interests.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Five Prime Therapeutics, Inc.

By: /s/ Francis Sarena Francis Sarena Executive Vice President, General Counsel & Secretary

Dated: January 19, 2016

3